Array BioPharma (NASDAQ:ARRY) initiated with Overweight rating and $30 (76% upside) price target. Shares are up 9% premarket on late-stage Mektovi/Braftovi data.
Incyte (NASDAQ:INCY) added to Conviction List with a $111 (51% upside) price target at Goldman Sachs citing M&A possibilities. Shares up 3% premarket.
MEDNAX (NYSE:MD) upgraded to Buy at Citigroup.
Medtronic (NYSE:MDT) upgraded to Buy with a $100 (18% upside) price target at BTIG Research. Shares up 1% premarket.
Subscribe for full text news in your inbox